Elotuzumab and daratumumab: emerging new monoclonal antibodies for multiple myeloma.
about
Ectoenzymes in leukocyte migration and their therapeutic potential.Carfilzomib in multiple myeloma.Prognostic indicators of lenalidomide for multiple myeloma: consensus and controversy.Refractory IgD Multiple Myeloma Treated with Daratumumab: A Case Report and Literature Review.CD38 expression predicts poor prognosis and might be a potential therapy target in extranodal NK/T cell lymphoma, nasal type.9th annual European Antibody Congress, November 11-13, 2013, Geneva, Switzerland.
P2860
Elotuzumab and daratumumab: emerging new monoclonal antibodies for multiple myeloma.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Elotuzumab and daratumumab: emerging new monoclonal antibodies for multiple myeloma.
@en
type
label
Elotuzumab and daratumumab: emerging new monoclonal antibodies for multiple myeloma.
@en
prefLabel
Elotuzumab and daratumumab: emerging new monoclonal antibodies for multiple myeloma.
@en
P2093
P2860
P1476
Elotuzumab and daratumumab: emerging new monoclonal antibodies for multiple myeloma.
@en
P2093
Hisao Nagoshi
Masafumi Taniwaki
Yuji Shimura
P2860
P304
P356
10.1586/14737140.2013.829641
P50
P577
2013-09-01T00:00:00Z